TL;DR:
- Neurophet, an AI solution company specializing in brain diseases, will be showcasing its cutting-edge brain image analysis technology at RSNA 2023.
- Flagship products “Neurophet AQUA” and “Neurophet SCALE PET” will be presented, offering attendees a firsthand experience of AI-powered brain image analysis.
- Focus on addressing side effects in Alzheimer’s disease treatment, including Amyloid-Related Imaging Abnormalities (ARIA).
- Neurophet’s CEO, Jake Junkil Been, highlights the company’s dedication to innovation and expanding its technology portfolio.
- Neurophet will contribute to the AI Theater and Scientific Poster Session with presentations on real-world Amyloid Target Drug Prescriptions and White Matter Lesion Asymmetry.
- RSNA, as the world’s largest radiology society, provides a global platform for sharing the latest advancements in the field.
Main AI News:
In an exciting development, Neurophet, a leading artificial intelligence (AI) solution provider focused on brain diseases, has announced its participation in the prestigious Radiological Society of North America 2023 (RSNA 2023) event. Neurophet is gearing up to showcase the remarkable strides it has made in brain image analysis technology, specifically in the context of dementia treatments, during the past year.
At RSNA 2023, Neurophet will proudly present its flagship products: the groundbreaking brain MRI analysis software known as “Neurophet AQUA” and the state-of-the-art brain PET scan analysis software named “Neurophet SCALE PET.” Attendees will have the unique opportunity to experience firsthand the power of AI-driven brain image analysis technology, which is poised to revolutionize the field, including the analysis of side effects in Alzheimer’s disease treatment.
Speaking of Alzheimer’s disease treatments, this year saw the full FDA approval of Leqembi, a novel drug designed to reduce beta-amyloid proteins in the brain. However, it’s important to note that taking such drugs can lead to Amyloid-Related Imaging Abnormalities (ARIA) as a potential side effect, manifesting as edema and hemorrhages. In response to this critical concern, Neurophet is set to launch an ARIA analysis product next year, and this cutting-edge technology will be introduced at the Neurophet booth at RSNA 2023.
Neurophet’s engagement at RSNA doesn’t stop there. The company is scheduled to make significant contributions to the AI Theater and Scientific Poster Session, focusing on studies related to Alzheimer’s disease and brain analysis technology. The esteemed medical director of Neurophet will deliver presentations on the topic of “How to be Prepared for the Real-World Amyloid Target Drug Prescriptions: ARIA, Amyloid Positivity and Beyond” at the AI Theater. Additionally, the intriguing study titled “White Matter Lesion Asymmetry-An Indicator of Amyloid PET Positivity in Mild Cognitive Impairment Patients” will take center stage at the Scientific Poster Session.
Jake Junkil Been, CEO of Neurophet, expressed the company’s commitment to innovation, stating, “Neurophet has meticulously prepared demonstrations showcasing various technologies for analyzing infant brain images and addressing cerebrovascular diseases, all of which are poised for future launches, alongside our pioneering work in Alzheimer’s disease at RSNA. With our comprehensive brain image analysis technology covering the spectrum of brain diseases, we are determined to redouble our efforts in sales and marketing, aiming for impactful business outcomes.”
RSNA, celebrating its 109th anniversary this year, stands as the world’s largest radiology society, drawing experts and dignitaries from academia, medicine, and industry worldwide to disseminate the latest research findings and breakthroughs. This year, RSNA is set to take place in Chicago, USA, commencing on the 26th (local time) and running through to the 30th. Stay tuned for the groundbreaking advancements in brain image analysis technology that Neurophet is poised to unveil at this prestigious event.
Conclusion:
Neurophet’s participation and groundbreaking innovations showcased at RSNA 2023 signify a significant stride in the AI-driven brain image analysis market. Their commitment to addressing Alzheimer’s disease treatment side effects and venturing into other brain diseases position them as a leading player in the field. This move is expected to foster competition and encourage further advancements in brain image analysis technology within the market.
